The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A pilot study of durvalumab/tremelimumab (durva/treme) and radiation (XRT) for metastatic biliary tract cancer (mBTC): Preliminary safety and efficacy.
 
Theodore S. Hong
Consulting or Advisory Role - Clinical Genomics; Clinical Genomics; Clinical Genomics; Clinical Genomics; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Merck; Merck; Merck; Merck
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Intrinsic LifeSciences (Inst); Intrinsic LifeSciences (Inst); Intrinsic LifeSciences (Inst); Intrinsic LifeSciences (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst)
 
Lipika Goyal
Consulting or Advisory Role - Debiopharm Group; Debiopharm Group; Debiopharm Group; Debiopharm Group
Research Funding - Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Debiopharm Group; Debiopharm Group; Debiopharm Group; Debiopharm Group; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Aparna Raj Parikh
Consulting or Advisory Role - Driver, Inc; Driver, Inc; Driver, Inc; Driver, Inc; Eisai; Eisai; Eisai; Eisai; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; PureTech; PureTech; PureTech; PureTech
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); OncoMed (Inst); OncoMed (Inst); OncoMed (Inst); OncoMed (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Eisai; Eisai; Eisai; Eisai
 
Beow Y. Yeap
No Relationships to Disclose
 
Christine A. Ulysse
No Relationships to Disclose
 
Lorraine C. Drapek
No Relationships to Disclose
 
Jill N. Allen
No Relationships to Disclose
 
Jeffrey William Clark
Consulting or Advisory Role - Emas pharma; Emas pharma; Emas pharma; Emas pharma
Research Funding - Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst)
 
Benjamin Christopher
No Relationships to Disclose
 
Christine Bolton
No Relationships to Disclose
 
David P. Ryan
Stock and Other Ownership Interests - Acworth Pharmaceuticals; Acworth Pharmaceuticals; Acworth Pharmaceuticals; Acworth Pharmaceuticals; MPM Capital; MPM Capital; MPM Capital; MPM Capital
Honoraria - Research to Practice; Research to Practice; Research to Practice; Research to Practice; UpToDate; UpToDate; UpToDate; UpToDate
Consulting or Advisory Role - Gritstone Bio; Gritstone Bio; Gritstone Bio; Gritstone Bio; Maverick Therapeutics; Maverick Therapeutics; Maverick Therapeutics; Maverick Therapeutics; MPM Capital; MPM Capital; MPM Capital; MPM Capital; Oncorus; Oncorus; Oncorus; Oncorus; TCR2 Therapeutics; TCR2 Therapeutics; TCR2 Therapeutics; TCR2 Therapeutics; Twentyeight-Seven Therapeutics; Twentyeight-Seven Therapeutics; Twentyeight-Seven Therapeutics; Twentyeight-Seven Therapeutics
Research Funding - Stand up to Cancer (Inst); Stand up to Cancer (Inst); Stand up to Cancer (Inst); Stand up to Cancer (Inst)
Patents, Royalties, Other Intellectual Property - Johns Hopkins University Press; Johns Hopkins University Press; Johns Hopkins University Press; Johns Hopkins University Press; McGraw Hill Chapter Royalties; McGraw Hill Chapter Royalties; McGraw Hill Chapter Royalties; McGraw Hill Chapter Royalties
Other Relationship - TCR2 Therapeutics; TCR2 Therapeutics; TCR2 Therapeutics; TCR2 Therapeutics
 
Ryan Bruce Corcoran
Stock and Other Ownership Interests - Avidity Biosciences; Avidity Biosciences; Avidity Biosciences; Avidity Biosciences; C4 Therapeutics; C4 Therapeutics; C4 Therapeutics; C4 Therapeutics; Fount Therapeutics; Fount Therapeutics; Fount Therapeutics; Fount Therapeutics; nRichDx; nRichDx; nRichDx; nRichDx; Revolution Medicines; Revolution Medicines; Revolution Medicines; Revolution Medicines
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; Avidity Nanomedicines; Avidity Nanomedicines; Avidity Nanomedicines; Avidity Nanomedicines; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; C4 Therapeutics; C4 Therapeutics; C4 Therapeutics; C4 Therapeutics; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Elicio Therapeutics; Elicio Therapeutics; Elicio Therapeutics; Elicio Therapeutics; FOGPharma; FOGPharma; FOGPharma; FOGPharma; Fount Therapeutics; Fount Therapeutics; Fount Therapeutics; Fount Therapeutics; Genentech; Genentech; Genentech; Genentech; Loxo; Loxo; Loxo; Loxo; Merrimack; Merrimack; Merrimack; Merrimack; N-of-One; N-of-One; N-of-One; N-of-One; Novartis; Novartis; Novartis; Novartis; nRichDx; nRichDx; nRichDx; nRichDx; Revolution Medicines; Revolution Medicines; Revolution Medicines; Revolution Medicines; Roche; Roche; Roche; Roche; Roivant; Roivant; Roivant; Roivant; Shionogi; Shionogi; Shionogi; Shionogi; Shire; Shire; Shire; Shire; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Symphogen; Symphogen; Symphogen; Symphogen; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Warp Drive Bio; Warp Drive Bio; Warp Drive Bio; Warp Drive Bio
Research Funding - Asana Biosciences; Asana Biosciences; Asana Biosciences; Asana Biosciences; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Sanofi; Sanofi; Sanofi; Sanofi
 
Jeffrey A. Meyerhardt
Honoraria - Cota Healthcare; Cota Healthcare; Cota Healthcare; Cota Healthcare; Ignyta; Ignyta; Ignyta; Ignyta; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma
Research Funding - Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst)
 
Jennifer Yon-Li Wo
No Relationships to Disclose
 
Andrew X. Zhu
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst)